Celsion Corporation Stock News

New York, New York--(Newsfile Corp. - November 4, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of

NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Celsion Corporatio

LOS ANGELES--(BUSINESS WIRE)---- $CLSN #CLSN--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation.

NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation ("Celsion

Atlanta, Georgia--(Newsfile Corp. - November 2, 2020) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Celsion Corporation (NASDAQ: CLSN

NEW YORK--(BUSINESS WIRE)-- #Celsion--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States Distri

NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation ("Celsion" or the "Company") (NASDAQ: CLSN).

Celsion Corporation (NASDAQ:CLSN) Q2 2020 Results Conference Call August 14, 2020 11:00 AM ET Company Participants Kim Golodetz - IR, LHA Investor Relations Michael Tardugno - Chairman, President and

Shares of Celsion (NASDAQ:CLSN) rose 2% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 37.93% year over year to ($0.18), which missed the esti

Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA Study for Overall Survival; Data Maturity at Issue Conference Call Begins T

LAWRENCEVILLE, N.J, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second quarte

Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue Cohort of 26 Consecutive Patient Deaths Differs Substantially from Predicted Behavior and from the Balance of the Trial

Celsion advances Phase II advanced ovarian cancer trial. Zentalis inks clinical collaboration with Eli Lilly.

Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients Non-Viral Nanoparticle Delivery System, TheraPlas Platform, Demonstrates Potential for Long-Ter

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.